Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Guessing that is what dropped the price?
away on me hols but a drop like this think i will get some. time to buy .
how did we end up down here?
this is another good share
bigger nibbles
little nibbles.
having no positive affect as yet
Irish buyers
Mind you there is news on VENN available in Irish publications, so maybe a little PR may boost the sp out of it's range Irish Times http://www.irishtimes.com/business/health-pharma/venn-life-sciences-signs-contracts-worth-over-3-4m-1.2493714
"what affect" that should be
to see what if any the Irish listing has on the SP
Excellent news.
Great stuff - a €3.4m contract win is huge for a company this size.. The contract sizes are getting much bigger, and it's a vote of confidence from the existing customer too.
Happy with this news, think that is our biggest contract to date.
Very nice! Speaking about the agreement, Venn CEO, Tony Richardson stated: "During 2015, I commented that executing our work to a consistent high standard would bring significant rewards and I am delighted to be able to show the concrete evidence of this. This is the second extension of what is a complex international programme and this endorsement is well deserved by our team. It is particularly pleasing to win this business at the commencement of the new year. 2015 was a year of significant growth at Venn and new business wins of this magnitude will enable us to continue expanding our business."
Beaufort Securities have summarised as follows this morning: "Venn Life Sciences (VENN.L, 23.0p) - Speculative Buy On Friday, Venn Life Sciences (Venn) released a trading update for the year ended 31st December 2015. The company expects revenue for the full year to be at least twice as much compared to last year (2014: €4.9m). Cash at the end of period stood at €3.4m. In a separate announcement, Venn informed that David Evans, Non-Executive Chairman, resigned from the board, in line with his personal commitment to reduce his number of non-executive chairman roles currently undertaken. Our view: In 2015, Venn experienced a sharp jump in revenue, led by some major contracts won during the period. Moreover, the addition of drug development and service capabilities has enhanced the company’s service offerings. Furthermore, Venn is seeking acquisition opportunities in Central and Eastern Europe in wake of huge opportunities in the region at minimal costs. Venn is well funded with sufficient cash to expand its international coverage. Overall, the company is well placed, with a strong balance sheet and enhanced contract base, to maintain its growth momentum in 2016. Therefore, we maintain our Speculative Buy rating on the stock. "
are we finally on the move north.
This is a rare company on the AIM as it does seem to actually be looking to grow and make profits as opposed to so many companies that just talk the talk year after year with placing after placing to pay the salaries. Revenue has doubled year on year (over the last two years) and now they are generating free cash which is a novelty for a company on the AIM Looking forward to reading the results and seeing more contracts signed throughout 2016 Back to sleep.
Holdings rns, That took some time to notify 22/10/15
Excellent trading statement today, with doubled sales of likely €10m+ and plenty of cash (€3.4m) going forward. Looking very strong now.
Venn Life Sciences Holdings PLC 08 January 2016 8 January 2016 Venn Life Sciences Holdings Plc ("Venn" or the "Company") Year End Update Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that revenues for full year to 31 December 2015 are expected to be at least double the previous year (2014: EUR4.9m). With a cash position at year end of EUR3.4m and the business now generating free cashflows Venn is well funded for future growth and well positioned to deliver further international expansion. This strong performance has been delivered through continued success in winning enterprise level contracts, facilitated by a growing reputation for delivering excellence and ongoing expansion of our international coverage and service capabilities. Commenting on the Year End Update, CEO of Venn Life Sciences, Tony Richardson stated: "We have now more than doubled our book of business in successive years and built a strong foundation on which we can deliver further growth. The addition of drug development and early phase capabilities into our service offering will enable us to capture greater market share in 2016 and truly differentiate our position in the market." Enquiries: Venn Life Sciences Holdings www.vennlifesciences.com Plc Tony Richardson, Chief Executive Tel: +353 154 99 341 Officer Jonathan Hartshorn, Chief Financial Tel: +353 153 93 269 Officer Orla McGuinness, Marketing Tel: +353 153 93 269 Manager Zeus Capital (Nominated Adviser Tel :+44(0)20 3829 and Joint Broker)
For some reason the trading update doesn't appear to be showing on this site's RNS link so have link below in case any have missed it. Excellent update and particularly like this sentence:- " a cash position at year end of €3.4m and the business now generating free cashflows" http://www.investegate.co.uk/venn-life-sciences--venn-/rns/trading-update/201601080701022206L/
lets hope so, cant believe its still at this SP after the half yearly report. GLA
Nicely, free cash too ...... slow and steady
Seem to have a distressed seller here. Buyers all over this last week paying 24-25p on the good news and now somebody is selling size at 21p this is a chance I thought would not be seen again to buy stock in the very low 20's !